Viktoria Stühler1, Lisa Herrmann1, Steffen Rausch1, Arnulf Stenzl1, Jens Bedke2. 1. Department of Urology, University Hospital Tuebingen, Eberhard-Karls-University Tuebingen, Hoppe-Seyler Street 3, 72076, Tuebingen, Germany. 2. Department of Urology, University Hospital Tuebingen, Eberhard-Karls-University Tuebingen, Hoppe-Seyler Street 3, 72076, Tuebingen, Germany. bedke@live.com.
Abstract
PURPOSE: Immune-based (IO)-combinations are the backbone in the systemic therapy of metastatic renal cell carcinoma (mRCC). Despite phase III clinical trial data, real world data are of special importance to reflect clinical practice. METHODS: This retrospective study included 201 mRCC patients receiving first-line systemic therapy from January 2006. Clinicopathological and treatment-related data were recorded. Progression-free (PFS) and overall survival (OS) were analyzed using descriptive statistics and Kaplan-Meier analysis. RESULTS: Over the years, IO-based therapies have increased significantly. The collective comprises 76 patients with first-line IO-based therapy (IO-IO:55, TKI-IO:21) and 125 patients with TKI-monotherapy. PFS was significantly improved with TKI-IO combinations if compared to both TKI-monotherapy (23.9 vs. 10.3 months, HR 0.48, p = 0.034) and IO-IO combination (23.9 vs. 6.1 months, HR 0.37, p = 0.012). OS for TKI-IO treated patients was longer compared to TKI-monotherapy (HR 0.37, p = 0.050) at median follow-up of 24.1 versus 29.9 months. In a subanalysis of nivolumab treated patients, starting from second-line (n = 40), PFS was 5.5 months. The addition of nivolumab either in second-or later lines improved OS compared to repeated TKI- or mTOR-therapies alone (6.13 vs. 2.61 years, HR 0.46, p = 0.003). CONCLUSION: Both first-line IO-based combinations and nivolumab after first-line TKI-monotherapy prolong OS in a real-world setting.
PURPOSE: Immune-based (IO)-combinations are the backbone in the systemic therapy of metastatic renal cell carcinoma (mRCC). Despite phase III clinical trial data, real world data are of special importance to reflect clinical practice. METHODS: This retrospective study included 201 mRCC patients receiving first-line systemic therapy from January 2006. Clinicopathological and treatment-related data were recorded. Progression-free (PFS) and overall survival (OS) were analyzed using descriptive statistics and Kaplan-Meier analysis. RESULTS: Over the years, IO-based therapies have increased significantly. The collective comprises 76 patients with first-line IO-based therapy (IO-IO:55, TKI-IO:21) and 125 patients with TKI-monotherapy. PFS was significantly improved with TKI-IO combinations if compared to both TKI-monotherapy (23.9 vs. 10.3 months, HR 0.48, p = 0.034) and IO-IO combination (23.9 vs. 6.1 months, HR 0.37, p = 0.012). OS for TKI-IO treated patients was longer compared to TKI-monotherapy (HR 0.37, p = 0.050) at median follow-up of 24.1 versus 29.9 months. In a subanalysis of nivolumab treated patients, starting from second-line (n = 40), PFS was 5.5 months. The addition of nivolumab either in second-or later lines improved OS compared to repeated TKI- or mTOR-therapies alone (6.13 vs. 2.61 years, HR 0.46, p = 0.003). CONCLUSION: Both first-line IO-based combinations and nivolumab after first-line TKI-monotherapy prolong OS in a real-world setting.
Authors: Linda S Elting; Catherine Cooksley; B Nebiyou Bekele; Michael Frumovitz; Elenir B C Avritscher; Charlotte Sun; Diane C Bodurka Journal: Cancer Date: 2006-06-01 Impact factor: 6.860
Authors: Peter J Goebell; Michael Staehler; Lothar Müller; Arnd Nusch; Michael Scheffler; Annette Sauer; Ulla von Verschuer; Susanne Tech; Lisa Kruggel; Martina Jänicke; Norbert Marschner Journal: Clin Genitourin Cancer Date: 2018-06-27 Impact factor: 2.872
Authors: Shaan Dudani; Jeffrey Graham; J Connor Wells; Ziad Bakouny; Sumanta K Pal; Nazli Dizman; Frede Donskov; Camillo Porta; Guillermo de Velasco; Aaron Hansen; Marco Iafolla; Benoit Beuselinck; Ulka N Vaishampayan; Lori A Wood; Elizabeth Liow; Flora Yan; Takeshi Yuasa; Georg A Bjarnason; Toni K Choueiri; Daniel Y C Heng Journal: Eur Urol Date: 2019-08-22 Impact factor: 20.096
Authors: Toni K Choueiri; Thomas Powles; Mauricio Burotto; Bernard Escudier; Maria T Bourlon; Bogdan Zurawski; Victor M Oyervides Juárez; James J Hsieh; Umberto Basso; Amishi Y Shah; Cristina Suárez; Alketa Hamzaj; Jeffrey C Goh; Carlos Barrios; Martin Richardet; Camillo Porta; Rubén Kowalyszyn; Juan P Feregrino; Jakub Żołnierek; David Pook; Elizabeth R Kessler; Yoshihiko Tomita; Ryuichi Mizuno; Jens Bedke; Joshua Zhang; Matthew A Maurer; Burcin Simsek; Flavia Ejzykowicz; Gisela M Schwab; Andrea B Apolo; Robert J Motzer Journal: N Engl J Med Date: 2021-03-04 Impact factor: 91.245
Authors: Marc-Oliver Grimm; Viktor Grünwald; Harald Müller-Huesmann; Philipp Ivanyi; Martin Schostak; Eyck von der Heyde; Wolfgang Schultze-Seemann; Hanjo Belz; Martin Bögemann; Meng Wang; Martin Herber; Jens Bedke Journal: Eur Urol Focus Date: 2021-12-23
Authors: Nicholas H Chakiryan; Da David Jiang; Kyle A Gillis; Elizabeth Green; Ali Hajiran; Lee Hugar; Logan Zemp; Jingsong Zhang; Rohit K Jain; Jad Chahoud; Philippe E Spiess; Wade Sexton; Scott M Gilbert; Brandon J Manley Journal: JAMA Netw Open Date: 2021-05-03
Authors: Laurence Albiges; Nizar M Tannir; Mauricio Burotto; David McDermott; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Thomas Powles; Frede Donskov; Saby George; Christian K Kollmannsberger; Howard Gurney; Marc-Oliver Grimm; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Toni K Choueiri; Shruti Shally Saggi; M Brent McHenry; Robert J Motzer Journal: ESMO Open Date: 2020-11
Authors: T K Choueiri; R J Motzer; B I Rini; J Haanen; M T Campbell; B Venugopal; C Kollmannsberger; G Gravis-Mescam; M Uemura; J L Lee; M-O Grimm; H Gurney; M Schmidinger; J Larkin; M B Atkins; S K Pal; J Wang; M Mariani; S Krishnaswami; P Cislo; A Chudnovsky; C Fowst; B Huang; A di Pietro; L Albiges Journal: Ann Oncol Date: 2020-04-25 Impact factor: 32.976